Background: Despite multiple factors correlating with the high prevalence of anaemia in heart failure, the prevailing mechanisms have yet to be established. The purpose of this study is to systematically review the literature and determine whether low circulating haemoglobin is primarily underlain by erythropoietin resistance or defective production in heart failure. Design and methods: We conducted a systematic search of MEDLINE since its inception until May 2017 for articles reporting erythropoietin and haemoglobin concentrations in heart failure patients not treated with erythropoietinstimulating agents. The primary outcome was the mean difference in observed/predicted (O/P) erythropoietin ratio between heart failure patients and normal reference values. Meta-regression analyses assessed the influence of potential moderating factors. Results: Forty-one studies were included after systematic review, comprising a total of 3137 stable heart failure patients with mean age and left ventricular ejection fraction ranging from 52 years to 80 years and 21% to 59%. The O/P erythropoietin ratio was below reference values in 24 of 25 studies in anaemic heart failure patients (n ¼ 1094, range ¼ 0.49-1.05), whereas only one out of 16 studies in non-anaemic heart failure patients presented a low O/P erythropoietin ratio (n ¼ 2043, range ¼ 0.91-1.97). In studies comparing anaemic versus non-anaemic heart failure patients (n ¼ 1531), the mean O/P erythropoietin ratio was consistently reduced in anaemic heart failure patients (mean difference ¼ -0.68, 95% confidence interval ¼ À0.78, À0.57; p < 0.001). In meta-regression, the O/P erythropoietin ratio was negatively associated with age, female sex, left ventricular ejection fraction, inflammation and disease severity. Conclusion: Anaemia in heart failure is overwhelmingly characterized by impaired erythropoietin production, which is exacerbated with age, female sex, left ventricular ejection fraction, inflammation and disease severity.
Introduction
Anaemia affects more than one-third of the heart failure population, with a higher prevalence in severe disease, independently augmenting the risk of mortality by 46%. 1, 2 The pathophysiology of anaemia fundamentally entails a reduction in the number of red blood cells and thereby oxygen (O 2 ) carrying capacity, which limits the potential delivery of O 2 to meet metabolic demands. Given the challenging methodological requirements to directly measure red blood cell mass, anaemia is commonly diagnosed according to cut-off values of circulating haemoglobin (Hb). 3 Despite a myriad of haematinic, renal, endocrine, immunological, haemodynamic and pharmacological factors having been linked to anaemia (i.e. low Hb levels) in heart failure, the main mechanisms remain to be established. [4] [5] [6] [7] [8] The formation of red blood cells, that is, erythropoiesis, is governed by the hormone erythropoietin (Epo), which promotes the survival, proliferation, differentiation and maturation of erythroid precursors in the bone marrow. [9] [10] [11] Epo is primarily regulated by tissue O 2 pressure and synthesized in peritubular fibroblast-like cells in the juxtamedullary region of the kidney. [12] [13] [14] In response to anaemia, Epo production is enhanced and commensurate with the magnitude of reduction in arterial O 2 content. 15 This results in a fairly consistent inverse linear relationship between Hb and endogenous Epo in patients with anaemia or blood disorders. 16, 17 Abnormalities in Epo relative to Hb generally indicate either defective Epo production or resistance in the bone marrow, respectively distinguished by decreases or increases in the observed/ predicted (O/P) Epo ratio. 16, 17 In this respect, although numerous investigations have assessed Epo and Hb levels in patients with heart failure, few studies have arithmetically related Epo to Hb, reporting varied O/P Epo ratios in the presence of anaemia. 17, 19, 25, 32, 36, 38 It is possible that the small sample size and pathophysiological heterogeneity of heart failure as well as distinct methodology may limit the synthesis of previous studies. Hence, the regulation of erythropoiesis and its key moderating factors are unclear in heart failure. The elucidation of these concepts might facilitate the discovery of effective target mechanisms for anaemia, a crucial achievement considering that erythropoiesis-stimulating agents are currently not recommended for heart failure patients. 6, 40 A systematic review and meta-analysis may contribute to obtain a comprehensive perspective and clarify this issue, but to our knowledge, this has not yet been performed.
Therefore, the purpose of this study was to perform a systematic review and meta-analysis of available studies assessing endogenous Epo and Hb circulating levels in heart failure patients, determine the O/P Epo ratio and evaluate the influence of clinical and methodological potential moderating factors.
Methods
The review is reported according to the Meta-analysis Of Observational Studies in Epidemiology group guidelines. 41 
Data sources and searches
Combinations of the subject headings 'heart failure', 'erythropoietin', 'hemoglobin' and 'hematocrit' were applied in MEDLINE since its inception until May 2017; the search strategy is shown in Supplementary Material Figure S 1 online. We also performed hand searching in reference citations of identified reviews, articles included in meta-analysis and related citations in MEDLINE and Google Scholar.
Article selection
To be included in the analysis, an original research article had to report blood levels of Epo and Hb in heart failure patients not treated with Epo-stimulating agents within three months prior to evaluation. In the event of multiple publications pertaining to the same research, the most comprehensive report was included. Inclusion of articles was not limited by publication status.
Data extraction and quality assessment
The following variables were summarized in a pre-formatted spreadsheet: authors, year of publication, main characteristics of heart failure patients (n, age, sex, height, weight, body mass index, body surface area, heart rate, blood pressure, left ventricular end-diastolic dimension, left ventricular ejection fraction (LVEF), N-terminal pro-brain natriuretic peptide (NT-proBNP), peak oxygen consumption, New York Health Association (NYHA) functional class, comorbidities, smoking status, medication, inclusion/exclusion criteria), anaemia-related parameters (Hb, Epo, iron, ferritin, transferrin saturation (TSAT), hepcidin), inflammatory markers (high-sensitivity C-reactive protein (CRP), tumour necrosis factor alpha, interleukin 6), kidney function (estimated glomerular filtration rate (eGFR)). A modified 'Quality assessment tool for observational cohort and cross-sectional studies (NIH)' was used to determine study methodological quality. 42 
Data synthesis and analysis
The meta-analysis was performed using Review Manager software (RevMan 5.3, Cochrane Collaboration, Oxford, UK) and Comprehensive Meta-analysis software (Biostat, Englewood, New Jersey, USA). The primary outcome was the mean difference (MD) in O/P Epo ratio between heart failure patients and normal reference values (O/P Epo ratio ¼ 1) according to the regression equation Log(Epo) ¼ 4.746 -(0.275 Â Hb). 16, 25, 32, 36 In addition, the MD in O/P Epo ratio between anaemic and nonanaemic heart failure patients, as defined by established Hb cut-off levels, was determined from studies presenting separate data for these subpopulations. Each MD was weighted by the inverse variance and pooled with a random-effects model. 43, 44 Data reported as median and range were transformed to mean AE SEM/SD using an improved method to standardize values in meta-analysis. 45 Missing measures of variability for the O/P Epo ratio were imputed from the coefficient of variation of studies that reported complete O/P Epo ratio data. 17, 25, 32, 36, 38 Heterogeneity among studies was assessed using the chi-squared test for heterogeneity and I 2 statistics.
Meta-regression analyses were performed to determine the association between the MD in O/P Epo ratio and potential moderating factors (sample size, age, sex, weight, body mass index, body surface area, heart rate, systolic blood pressure, diastolic blood pressure, left ventricular end-diastolic dimensions, LVEF, NT-proBNP, eGFR, iron, ferritin, TSAT, hepcidin, CRP, tumour necrosis factor alpha, interleukin 6, peak oxygen consumption, NYHA functional class, prevalence of comorbidities/medication, methodological quality score). Potential moderating factors were entered as independent variables in regression models with the MD in O/P Epo ratio as the dependent variable. Publication bias was evaluated by the Begg and Mazumdar's rank correlation test and Egger's regression test. 46 A p value <0.05 was considered statistically significant.
Results

Study selection and characteristics
The flow diagram of the process of article selection is illustrated in Figure 1 , which resulted in the inclusion of 23 articles. Sixteen of these articles presented data for two or more independent groups, each of which was evaluated as an individual study. 18, [21] [22] [23] [24] [26] [27] [28] [29] [30] 32, 34, [36] [37] [38] [39] Table 1 shows the main baseline characteristics of the resulting 41 studies, comprising a total of 3137 stable heart failure patients, mean age ranging from 52 years to 80 years. The majority of the studies included females and males, approximately one-third of total patients being females. Mean LVEF ranged from 21% to 59%, mainly comprising heart failure patients with LVEF <50%. Twenty-five studies involved anaemic (n ¼ 1094) and 16 studies (n ¼ 2043) non-anaemic heart failure patients. With respect to renal function, mean eGFR ranged from 80 ml to 46 mlÁmin -1 Á1.73 m -2
and from 87 ml to 30 mlÁmin -1 (Cockroft-Gault equation). Eight studies reported the inclusion of patients with iron deficiency according to FAIR-HF (n ¼ 115) 22, 37, 47 or more stringent criteria (n ¼ 136).
18,31
The reported prevalence of medication is presented in Supplementary Table S 2 .
Methodological quality assessment and potential bias
The methodological quality of the studies was moderate-to-high. The average score was 6.2 AE 0.9 out of a possible eight points (Supplementary Table S O/P Epo ratio according to anaemia status Figure 2 illustrates the mean O/P Epo ratio in anaemic (a) and non-anaemic (b) heart failure patients. O/P Epo ratio was below normal reference values in 24 of 25 studies including heart failure patients with anaemia (n ¼ 1094, range ¼ 0.49-1.05), whereas only one out of 16 studies in non-anaemic heart failure patients presented a lower than normal O/P Epo ratio (n ¼ 2043, range ¼ 0.91-1.97). In studies comparing anaemic with non-anaemic heart failure patients, after data pooling, O/P Epo ratio was markedly reduced in anaemic versus non-anaemic heart failure patients (n ¼ 1531, MD ¼ -0.68, 95% confidence interval (CI) ¼ -0.78, À0.57; p < 0.001) ( Figure 3 ).
Meta-regression analyses
The MD in O/P Epo ratio was negatively associated with age (n ¼ 2821, 
Discussion
In this systematic review and meta-analysis, we pooled and analysed data from 41 studies determining endogenous Epo and Hb levels in a total of 3137 heart failure patients. The key finding of this meta-analysis is that anaemia in heart failure is predominantly underlain by lower than predicted Epo, as reflected by the O/P Epo ratio. In contrast, low O/P Epo ratio was mainly absent in heart failure patients without anaemia. Likewise, clinical variables commonly linked to anaemia such as age, female sex, LVEF, NT-proBNP, CRP, iron status and eGFR were associated with O/P Epo ratio.
Erythropoiesis is a finely controlled biological process but its pathophysiological regulation remains to be clarified. 4 Multiple factors related to kidney or bone marrow dysfunction as well as hematinic deficiencies, all of which are potentially present to some extent in heart failure patients, 5-8 may affect erythropoiesis. Irrespective of the specific aetiology of anaemia, it is fundamental to determine whether there is any alteration in the main hormone controlling red blood cell production, that is, Epo. To our knowledge, the present investigation is the first systematic review aiming to delineate the status of endogenous Epo in heart failure. We selected studies assessing circulating Epo along with Hb levels, and determined the O/P Epo ratio conforming to an established regression equation. 16, 25, 32, 36 The results denote that the vast majority of studies (24 of 25) comprising heart failure patients with anaemia exhibit a reduced O/P Epo ratio compared with normal reference values or non-anaemic heart failure patients. This suggests a deficit in the production of Epo relative to arterial O 2 content, plausibly being a generalized cause of anaemia in heart failure. It should be noted that circulating Epo is elevated independent of Hb levels in heart failure patients compared with healthy controls, in direct relationship with NYHA scores. 48, 49 In this respect, Epo production may be partially related to the critical stress response involving glucocorticoid upregulation. 50, 51 Moreover, blood volume-regulating hormones leading to fluid retention such as angiotensin II and vasopressin may directly stimulate Epo synthesis. [52] [53] [54] [55] In addition, bone marrow dysfunction in heart failure, similarly observed in anaemic and non-anaemic patients, may require higher circulating Epo levels for a given erythropoietic effect. 5 These could be contributing factors to the frequently increased O/P Epo ratio in non-anaemic heart failure patients. Notwithstanding, this meta-analysis emphasizes that the overall increase in Epo synthesis in heart failure patients with anaemia does not reach the required magnitude to normalize Hb levels. The mechanisms underpinning the blunted Epo response to anaemia in heart failure are incompletely understood. Provided that Epo is mainly synthesized in the kidneys, 13, 14 it is reasonable to foresee a relationship between kidney failure, a prominent comorbidity in heart failure patients and impaired capacity to produce Epo. 7 In meta-regression analyses, O/P Epo ratio was negatively associated with the prevalence of CKD and positively associated with eGFR. The structural renal damage inherent to CKD involves a partial transformation of renal Epo-producing cells into myofibroblasts -which do not possess Epo-producing ability -via the NFkB proinflammatory signalling pathway. 56 Independent of phenotypic modifications, proinflammatory cytokines such as interleukin-1 beta and tumour necrosis factor alpha directly inhibit Epo production in isolated perfused rat kidneys 57, 58 and hepatoma Hep3B/HepG2 cell lines in a dose-dependent manner. 59 This suggests that the liver may be impeded to compensate for impaired renal Epo production in the setting of systemic and intensified inflammation. In this line, we found a negative association between O/P Epo ratio and CRP, a widespread marker of inflammation. Likewise, O/P Epo ratio was positively associated with serum iron, possibly driven to a degree by the interference of inflammation with iron absorption and mobilization. 60 The fact that O/P Epo ratio was associated with CRP and serum iron, but not with ferritin, may be consistent with an inflammatory state contributing to relative iron deficiency anaemia and impaired Epo production in heart failure patients. Of note, inflammation-related alterations of iron homeostasis characterized by low TSAT and elevated hepcidin in the presence of normal ferritin levels might precede absolute iron deficiency anaemia and thus facilitate its early clinical detection and prevention. 61 Adequate Epo production and Hb levels might not be amenable to restoration in advanced stages of heart failure, as inferred from the negative association between O/P Epo ratio and NT-proBNP, a marker of heart failure progression linked to inflammation, iron deficiency anaemia and renal failure. [62] [63] [64] Taken together, O/P Epo ratio was linked to renal, inflammatory and hematinic variables as well as to markers of disease severity frequently related to anaemia, suggesting that limited Epo production is a central feature of this disorder in heart failure patients. Furthermore, the relationships revealed in this meta-analysis buttress the notion that anaemia in heart failure primarily resembles a type of anaemia of inflammation or chronic disease. 60 The question arises as to how the present findings relate to the treatment of anaemia in heart failure patients. In this regard, the largest clinical trial to date evidenced that correction of anaemia determined by Hb normalization with supraphysiological Epo doses ($42 mg of darbepoetin weekly) did not improve hard endpoints and increased the risk of thromboembolic events in heart failure patients with substantially reduced ejection fraction (HFrEF) (LVEF <40%). 40 These findings seemingly contradict the need for higher endogenous Epo levels in anaemic heart failure patients, implied by the present metaanalysis. Whilst speculative, there could be a 'sweet spot' with lower Epo dosage, as denoted by re-analyses of large clinical trials assessing cardiovascular events in anaemic patients. 65 Importantly, while Hb is typically used to diagnose anaemia, low Hb can be the result of fluid retention and concomitant plasma volume expansion despite unaltered total Hb mass, that is, haemodilution, a prevailing observation in HFrEF patients. 18, [66] [67] [68] [69] Haemodilution is less common in anaemic heart failure patients with preserved ejection fraction (HFpEF), mainly presenting a genuine deficit in red blood cell volume (RBCV), termed true anaemia. 68 Indeed, HFpEF patients with low RBCV respond favourably to Epo therapy. 22 Interestingly, metaregression analyses showed a negative association between O/P Epo ratio and LVEF, disclosing an increasing impairment of Epo production with higher LVEF in heart failure patients. Similarly, O/P Epo ratio was negatively associated with age and female sex, both being primary risk factors for HFpEF as well as strong determinants of true anaemia in heart failure. 51, 70 Collectively considered, Epo response to anaemia may be progressively exacerbated along the continuum of LVEF in heart failure patients, possibly being a sensible target for Epo therapy in a large fraction of HFpEF patients, who account for approximately half of the heart failure population.
Limitations
There are some limitations to this meta-analysis that require comment. First, the synthesis of Epo may be modulated by circadian rhythms. Nonetheless, blood sampling was performed in the early morning in the studies describing the time of blood withdrawal [23] [24] [25] [26] 30, 32, 33, 35, 36 and previous investigations describe minimal or no diurnal fluctuation of circulating Epo levels in adults. 71, 72 Finally, the presence of publication bias in the MD in O/P Epo ratio was not discarded, although the methodological quality of the included studies was determined as moderate-to-high, indicating a generally low bias risk.
Conclusion
The current meta-analysis demonstrates that impaired Epo response to anaemia is highly prevalent in heart failure patients. In contrast, heart failure patients without anaemia predominantly present with normal or enhanced Epo levels. The observation that age, female sex, LVEF, markers of inflammation/disease severity, iron status and eGFR were associated with the O/P Epo ratio suggests that blunted Epo production relative to low Hb is derived from major established risk factors for anaemia. Further studies are needed to establish the specific mechanisms leading to the limitation of Epo production in heart failure patients with anaemia.
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